Office of Immunology and Inflammation - Division of Pulmonology, Allergy, and Critical Care (DPACC)
The Division of Pulmonology, Allergy and Critical Care (DPACC) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products intended for the prevention, treatment or diagnosis of conditions including:
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Idiopathic pulmonary fibrosis (IPF)
- Acute respiratory distress syndrome (ARDS)
- Seasonal and perennial allergic rhinitis (SAR, PAR)
- Chronic idiopathic urticaria (CIU)
- Cough and cold symptoms (prescription drug products only)
- Cough inducers (for challenge tests)
- Hereditary angioedema (HAE)
- Anaphylaxis
- Cystic fibrosis (except infections associated with CF)
- Products for critical care (e.g., epinephrine)
- Surfactants for infant respiratory distress syndrome (RDS)
Contact Us
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Pulmonology, Allergy and Critical Care
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2300
Fax: (301) 796-9728
Resources
- Office of Immunology and Inflammation
- Office of New Drugs
- CDER Offices and Divisions
- Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality